Balaji Amines Limited · NSE:BALAMINES
Balaji Amines — Investor Presentation (August 2022)
39 slides from Balaji Amines's investor presentation, Aug 13, 2022
Slide 1: Exchange filing cover letter for Investor Presentation
13th August, 2022 To, The General Manager-Department of Corporate The Manager-Listing Department, Services, National Stock Exchange of India Limited, BSE Linited, "Exchange Plaza", 5th Floor, Phiroze ]eejeebhoy Towers, Plot No. C/1, G Block, Dalal Street, Mumbai -400 001. Bandra-Kurla Complex, Scrip
Slide 2: Investor Presentation August 2022
Investor Presentation August 2022
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Balaji Amines Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti
Slide 4: Q1FY23: Financial Highlights
Q1FY23 : Financial Highlights Revenue (Rs. Crore) EBITDA (Rs. Crore) PAT (Rs. Crore) EBITDA & PAT Margin 48.86% 52.11% 51.99% 783.91 219.48 148.04 32% 33% 674.86 199.17 130.85 Consolidated 25% 144.29 97.40 21% 22% 453.35 17% Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY2
Slide 5: Q1FY23 Performance Highlights
Q1FY23 Performance Highlights Revenue from Operations for Q1FY23 stood at ₹ 674.86 crore, up by 48.86%, as compared to ₹ 453.35 crore in Q1FY22. Total volumes stood at 27,358 MT for Q1FY23 as against 25,620 MT in Q1FY22. The revenue growth was on account of improved volume offtake on account of enha
Slide 6: Phase-2 Expansion Plans at our 90-acre Greenfield Project (Unit IV)
Phase-2 Expansion Plans at our 90-acre Greenfield Project (Unit IV) N-Butylamine Acetonitrile Methylamines Dimethyl Formamide We plan to undertake capex for a new Post the process of de-bottlenecking Market Leader in Methylamines Market Leader in Dimethyl Formamide product, namely N-Butylami
Slide 7: Standalone Statement of Profit & Loss
Standalone Statement of Profit & Loss Particulars (in Rs. Crore) Q1FY23 Q1FY22 Y-o-Y FY22 Total Revenue 517.47 395.67 30.78% 1,937.93 Raw Material 278.33 197.91 1,073.06 Employee expense 24.85 18.09 88.73 Other expenses 81.74 62.75 316.79 EBITDA 132.55 116.92 13.37% 459.35 EBITDA Margin 25.61% 29.55
Slide 8: Consolidated Statement of Profit & Loss
Consolidated Statement of Profit & Loss Particulars (in Rs. Crore) Q1FY23 Q1FY22 Y-o-Y FY22 Total Revenue 674.86 453.35 48.86% 2,335.34 Raw Material 319.24 219.67 1,222.53 Employee expense 26.22 18.66 91.54 Other expenses 109.92 70.73 383.88 EBITDA 219.48 144.29 52.11% 637.39 EBITDA Margin 32.52% 31
Slide 9: About Us
About Us
Slide 10: Amines Industry – Unique but Critical Industry with growth potential
Amines Industry – Unique but Critical Industry with growth potential The size of Aliphatic Amines industry globally The consumable nature of demand and the is $4.9 billion. Globally, the Amine industry is oligopolistic nature of the industry, results in oligopolistic with two-three producers a stron
Slide 11: Balaji Amines Ltd – A Leading player in Aliphatic Amines in India
Balaji Amines Ltd – A Leading player in Aliphatic Amines in India State-of-the-art Forward integrated manufacturing suite of products Largest manufacturer of Aliphatic Amines in facilities fully equipped with latest DCS 30+ Product Downstream products added based on strength of amine manufacturing w
Slide 12: Our Products are supplied to India's fast-growing Industries
Our Products are supplied to India’s fast-growing Industries Industry Wise - Revenue Breakup 3% 4% 3% 4% 3% 2% 4% 51% 26% Pharma Agrochem Paints & Resins Animal Feeds Oil & Gas Rubber Cleaning Chemicals Water Treatment Chemicals Dye and Textiles Others 11
Slide 13: Highly Experienced Management Team
Highly Experienced Management Team Mr. A. Srinivas Reddy Mr. D. Ram Reddy Mr. A. Pratap Reddy Mr. N. Rajeshwar Reddy Mr. G. Hemanth Reddy Whole Time Director Managing Director Executive Chairman Joint Managing Director Whole Time Director & CFO • Post Graduate in Computer • 35 years of experience ac
Slide 14: Diversified Product Portfolio
Diversified Product Portfolio Particulars Amines Amine Derivatives Specialty & Other Chemicals • Aliphatic Amines find increasing • Amine Derivatives are used to make consumption and applications in a further salts and other complex chemical • Albeit a small and fastest growing Chemically mature Ind
Slide 15: Clientele
Clientele Amines Amine Derivatives Specialty & Other Chemicals 14
Slide 16: Well positioned Business Model aimed at Sustainable growth
Well positioned Business Model aimed at Sustainable growth Focus towards high-value derivatives and Develop new indigenous technology for specialty chemicals with an aim to move up manufacturing products leading to lowering in the value-chain with vertical integration manufacturing costs & improving
Slide 17: Key Products (Current & Proposed) in Portfolio
Key Products (Current & Proposed) in Portfolio Product Existing Installed Capacity Proposed Capacity Application Areas Methyl Amine 48,000 40,000 Pharma, Agro, Dye & Rubber Ethyl Amine 22,500 - Pharma, Agro, Dye & Rubber DMAHCL 25,000 7,500 Pharma DMAC 6,000 - Pharma API Choline Chloride 60% (Corn C
Slide 18: We are Global suppliers – a significant validation of our Capabilities
We are Global suppliers – a significant validation of our Capabilities • UK • Japan • US • Turkey • Argentina • Finland • Canada • Indonesia • Israel • Switzerland • India • Sri Lanka • Pakistan • Russia • Bangladesh • Malaysia • Oman • Singapore • Germany • Bahrein • Italy • Jordan • Egypt • Guatem
Slide 19: Awards & Certificates – A Testimony of our capabilities
Awards & Certificates – A Testimony of our capabilities ISO Certificate Two Star ISO Certificate Product Innovator of the Year in Distinguished Contribution in the Export House Chemicals – 2018 Indian Chemicals Industry Excellent CSR WHO GMP in Water Certificate Conservation Niryat Shree REACH Pre-
Slide 20: We are Growing…Sustainably and Consistently
We are Growing…Sustainably and Consistently “Long-Term Issuer Rating upgraded to ‘IND AA’ from ‘IND AA-’ by India Ratings and Research (Ind-Ra) .” The ratings process highlighted the following factors:- • Largest manufacturer of aliphatic amines and their derivatives in India • Sole producer for a f
Slide 21: High entry barrier Business – Paving way for Sustainable growth
High entry barrier Business – Paving way for Sustainable growth Complex manufacturing process Niche product offering with high High fixed costs, with fixed asset requiring high levels of lead time in customer approvals turns hovering in the range of 1.5- technological know-how. Efficient 2x. Optimum
Slide 22: Well positioned Business Model aimed at Sustainable growth
Well positioned Business Model aimed at Sustainable growth Value-Added Products Applicability in Solvents segment Capex towards high-value derivatives and specialty Solvents account for 80%-90% of the mass chemicals will materialize into higher revenue and enhanced margins 01 utilised in a typical p
Slide 23: Greenfield Project to fuel growth and add Revenue Visibility
Greenfield Project to fuel growth and add Revenue Visibility Strategically Mega Project Project Capex Product Profile Indigenous New Products = 1st High Demand Located Plant Status Technology mover advantage for Products Environmental Ethylamines plant in Project cost of Rs. New Acetonitrile Plan to
Slide 24: Balaji Speciality Chemicals – Production commenced in FY20
Balaji Speciality Chemicals – Production commenced in FY20 Manufacturing products such as Ethylene 01 Diamine, Piperazine, Aminoethylpiperazine 04 BAL owns 55% in subsidiary Balaji Speciality (AEP) and Diethylenetriamine which are Chemicals Pvt. Ltd which is strategically located currently imported.
Slide 25: R&D led Investments to provide significant early mover advantage
R&D led Investments to provide significant early mover advantage New Products Optimization Integration Continuous efforts to optimize Identification of new utilization of energy, utilities & Backward and forward products and development of raw materials consumption and integration of products to lat
Slide 26: Hotel Division
Hotel Division
Slide 27: Balaji Sarovar Premiere – Best in class Business Hotel in Solapur
Balaji Sarovar Premiere – Best in class Business Hotel in Solapur • Commenced Operations in October 2013 Hotel Balaji Sarovar Premier is the only 5 star hotel in Solapur • Invested Rs. 110 crore in the Hotel Project via mix of Debt and Equity • Tied up with Sarovar Group for the Management of the Ho
Slide 28: Balaji Sarovar Premiere – Operating Matrix
Balaji Sarovar Premiere – Operating Matrix Constitutes 129 Rooms 0.84% of Negligible Routine Capex incurred Rs. 3,666 ARR Total Revenue 47% RS. 1,705 Occupancy Rate RevPAR Renowned Five Star Hotel In the City of Solapur For FY22 ARR : Average Room Revenue RevPAR: Revenue per Available Room 27
Slide 29: Financial Performance
Financial Performance
Slide 30: Consolidated Performance Highlights
Consolidated Performance Highlights Revenue (Rs. Crs.) EBITDA (Rs. Crs) PAT (Rs. Crs.) 2,328 637 418 +28% +35% +39% 1,318 379 244 861 943 941 190 193 186 113 117 97 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 EBITDA Margin (%) PAT Margin (%) RoE (%) 28.8% 27.4% 18.5% 1
Slide 31: Strong Core ROCE Profile
Strong Core ROCE Profile Particulars (Rs. Crs.) FY20 FY21 FY22 Consolidated Debt 259.57 127.07 100.64 For FY20, investments made to the tune of Rs. 112.35 crore in Consolidated Networth 668.37 909.92 1,314.86 subsidiary company of Balaji Amines not considered, as the volume Total Capital Employed
Slide 32: Consolidated Profit & Loss Account
Consolidated Profit & Loss Account Particulars (in Rs. Crore) FY22 FY21 YoY Total Revenue 2,327.60 1,317.53 76.66% Raw Material 1,222.53 630.26 Employee Cost 91.54 67.82 Other Expenses 376.14 240.15 EBITDA 637.39 379.30 68.04% EBITDA Margin 27.38% 28.79% Depreciation 42.00 34.41 EBIT 595.39 344.89 7
Slide 33: Consolidated Balance Sheet Statement
Consolidated Balance Sheet Statement ASSETS (Rs. Crs.) Mar-22 Mar-21 EQUITY AND LIABILITIES (Rs. Crs.) Mar-22 Mar-21 (1) NON-CURRENT ASSETS EQUITY (a) Equity Share capital 6.48 6.48 (a) Property, plant & equipment 681.18 542.92 (b) Other equity 1,243.37 887.91 (b) Capital work-in-progress 140.94 173
Slide 34: Standalone Statement of Profit & Loss
Standalone Statement of Profit & Loss Particulars (in Rs. Crore) FY22 FY21 YoY Total Revenue 1,930.19 1,239.81 55.68% Raw Material 1,073.07 622.69 Employee Cost 88.73 65.68 Other Expenses 309.04 212.79 EBITDA 459.35 338.65 35.64% EBITDA Margin 23.80% 27.31% Depreciation 29.17 23.34 EBIT 430.18 315.3
Slide 35: Consistent Dividend Payout
Consistent Dividend Payout 300% 200% 160% 130% 140% FY18 FY19 FY20 FY21 FY22 Particulars (Rs. per share) FY18 FY19 FY20 FY21 FY22 Consolidated Book Value 149.71 182.71 206.28 280.83 405.81 Consolidated EPS 34.93 36.27 32.34 73.52 113.71 Dividend 2.60 2.80 3.20 4.00 6.00 34
Slide 36: Moving towards Growth Prospects
Moving towards Growth Prospects
Slide 37: Balaji Amines Ltd - Progressing steadily
Balaji Amines Ltd - Progressing steadily Increased capacity Ramp up in production Greenfield Capex Phase - 2 utilization & capacity at Subsidiary Plant additions of Phase – 1 capex Expansion and commercialization of Ramp up in manufacturing of 90-acre project in MIDC Chincholi to Higher capacity uti
Slide 38: ESG & CSR Initiatives
ESG & CSR Initiatives Distribution of RNA Covid -19 testing machine to Dr. Babasaheb Distribution of highflow O2 therapy machine – 2 and bipap machine 1 Ambedkar University, Osmanabad to ESIS Hospital, Solapur on 20.01.2022 Donated ₹ 1 Crore to CM Relief Fund towards Set-up of ME- Electrical Cremati
Slide 39: Thank You
Thank You For further information, please contact: Company : Investor Relations Advisors : Orient Capital (a division of Link Group) Mr. Rasika Sawant Balaji Amines Ltd. +91 9594457518 CIN - L24132MH1988PLC049387 rasika.sawant@linkintime.co.in Email - cs@balajiamines.com Ms. Rajesh Agrawal +91 99674